Passage Bio, Inc.

NASDAQ: PASG · Healthcare · Biotechnology

PublicHQ Philadelphia, PA · PhiladelphiaCIK 0001787297Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 25DQ —GM —SS 41

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, market scale · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$45.5M

Employees

as of 2026-08-21

Market cap

$14.4M

as of 2026-08-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$45.5M-$45.5M2025

Operating income-$49.3M-$49.3M2025

Total assets$62.3M$62.3M2025

Liabilities$43.5M$43.5M2025

Equity$18.8M$18.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Passage Bio, Inc.’s financial profile?

Passage Bio, Inc. earned -$45.5M in FY2025 net income.

Peers · Healthcare

Akari Therapeutics, Plc——CS Diagnostics Corp.——BioVie Inc.——Anebulo Pharmaceuticals, Inc.——Intensity Therapeutics, Inc.——IN8bio, Inc.——

Neighbors

Philadelphia →

Comcast Corporation$123.7B86A Carpenter Technology Corporation$2.9B84B+Aramark$18.5B64C Five Below, Inc.$4.8B74B Axalta Coating Systems Ltd.$5.1B77B+Urban Outfitters, Inc.$6.2B73B

Key facts

CEOWilliam Chou

SectorHealthcare

IndustryBiotechnology

HeadquartersPhiladelphia, PA

ExchangeNASDAQ: PASG

Employees24

IPO date2020-02-28

Latest filings

10-Q2026-08-10 8-K2026-06-24 8-K2026-05-27 8-K2026-05-26 10-Q2026-05-12 8-K2026-04-28 8-K2026-04-20 DEF 14A2026-04-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.